Assembly Biosciences Inc

Gilead’s recent purchase of Assembly Biosciences shares boosts investor confidence in its HBV therapy and CDAD platform, hinting at future upside and strategic partnership opportunities.

Assembly Biosciences insider buys signal long‑term confidence in HBV‑cure trials; executives align personal wealth with future growth.